Clinical trial
Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)
NCT00162929 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00162929 |
|---|---|
| Title | Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe) |
| Official title | A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Expressing Rat Her-2/Neu in Patients With Metastatic or Locally Recurrent Breast Cancer |
| Acronym | AdHERe |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Ontario Cancer Research Network Canadian Breast Cancer Research Alliance |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Biological |
| Interventions | AdHer-2/neu transduced dendritic cells |
| Enrollment | 5 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2009 |
| Completion | May 1, 2012 |
| First posted | Sep 13, 2005 |
| Last update posted | Jun 4, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: